- Positive CHMP opinion is based on Phase 3 COLUMBUS trial which demonstrated nearly 15 months median progression-free survival and over 30 months median overall survival -
- U.S. FDA recently approved BRAFTOVI + MEKTOVI for advanced BRAF-mutant melanoma -
PR Newswire
BOULDER, Colo., July 27, 2018